Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with haematological or lymphoid malignancies with allogenic transplantation indication:~  * High risk follicular NHL, mantle HHC and other low grade NHC (e.g lymphoplasmacytic, extranodal or from marginal zone).~    1. Disease that does not obtain a CR with Fludarabine or antiCD-20 including chemotherapy.~   2. Relapse after autologous transplant.~   3. Non candidates to autologous transplant in 2nd CR (e.g. mobilization failure, or persistent marrow infiltrate).~ * Poor prognosis chronic lymphoblastic leukaemia (CLL): Del 11q, Del 17p, complex cariotype; B symptoms, progressive low cell count by marrow infiltration, lymphocytosis or enlarged lymph nodes, or progressive spleen growth.~ * High grade lymphoma transformed from a low grade non Hodgkin's lymphoma or from a chronic lymphocitic leukaemia~ * High risk T peripheral lymphoma, with IPI \> or = 2, non susceptible of autologous transplant, or relapsed after autologous transplant~ * Primarily refractory high risk Hodgkin's disease, relapse in patients not susceptible of autologous transplant or relapse after autologous transplant.~ * High risk acute mieloblastic leukaemia (AML) in 1st CR, or AMC \> or = 2 CR, including AML after MDS and secondary AML.~ * High risk acute lymphoblastic leukaemia (ALL) because of poor response to induction chemotherapy (\>10% blasts day +14 or no RC day +28-35), or by cytogenetic criteria: Ph+ or 11q23.~ * High risk myelodisplastic syndromes (SMD) type RAEB-1 or AREB-2 with IPSS \>Int-1.~* For the inclusion in transplant patients with ALL or AML must be in CR, patients with MDS must have \<10% blasts en la BM, and patients with lymphoid malignancies must show previous chemosensitivity, with PR or CR.~* Patients 40 to 65 years old. Patients outside this age range could be included according to participating centres criteria.~* Patients in the study population lacking a compatible related donor, and with a possible compatible unrelated donor (\>=9/10 by 10 alleles high resolution typing: HLA-A, B, C, DRB1, DQB1) to assign the patients to a risk in subgroup.~* Signed informed consent.~* Not fulfilling any of the following exclusion criteria.~Exclusion Criteria:~* Liver (≥ x3 UNL), kidney (GF \<40ml/min), cardiac (LVEF \<40%) or respiratory (DLCO \& FVC \<40% of expected) function tests impairment.~* HIV injection.~* Absence of signed informed consent.~* Progressive disease previous to transplant or not fulfilling the above mentioned response criteria.~* Other co-morbidities that contraindicate CT.~* Pregnant and/or breast-feeding women or with pregnancy risk by inadequate contraception.~* Life expectancy \<6 months.~* Mental or psychiatric deficiency impeding adequate understanding and consent to therapy~* Hypersensitivity as shown by anaphylactic reaction to any of the DRUGS used in the trial.~* Active infectious process.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive).
- 2 (Type: EXPERIMENTAL): Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).

Based on this trial design, predict the completion outcome and termination type (if applicable).